Broussard Grace, Hohmeier Kenneth C, Field Craig, Gordon Adam J, Carlston Kristi, Cernasev Alina, Tyszko Melissa, Snyder Ashley M, Cochran Gerald
University of Utah, Division of Epidemiology, 295 Chipeta Way, Salt Lake City, UT 84108, United States of America.
University of Tennessee Health Science Center, 301 S. Perimeter Park Drive, Suite 220, Nashville, TN 37211, United States of America.
J Subst Use Addict Treat. 2025 Feb;169:209606. doi: 10.1016/j.josat.2024.209606. Epub 2024 Dec 12.
A significant risk for overdose among patients prescribed opioid medications is co-use of alcohol. Community pharmacies are underutilized as a resource to prevent and address co-use. The barriers and facilitators that promote or impede the adoption of universal alcohol screening and intervention at point of opioid medication dispensing are unknown. We assessed community pharmacy leaders, pharmacists, and technician's perceptions towards the implementation of a pharmacy-based screening/intervention for the co-use of opioids and alcohol among patients.
We conducted a multi-method study that included one-time key informant interviews combined with a close-ended survey to inform our understanding of pharmacy system/practice-level barriers and facilitators for universal screening and intervention. Participants were recruited from Utah and Tennessee and were required to have active employment as pharmacy leaders, pharmacists, or technicians, be English-speaking, and believe they could provide feedback regarding co-use screening and intervention within community pharmacies. Interviews used the Consolidated Framework for Implementation Research and the Organizational Readiness for Implementing Change assessment. Qualitative analysis included both inductive and deductive coding. Themes followed a cycle of open, initial coding whereby codes were derived inductively from the data.
Themes from interviews (N = 68) included a) emphasizing a need to overcome the stigma associated with patients who engage in co-use and a mindset shift to treat the challenges and risks associated, b) need for corporate-level support, management buy-in, and c) appropriate technology to support the workflow including system-wide changes to support the integration of medication therapy management services within community pharmacies. However, barriers were offset by pharmacists eager to understand their role in screening patients and reiterated a focus on patient-centered care to achieve this goal. From the ORIC assessment, 75 % (n = 51) of respondents reported that community pharmacy staff wanted to implement the screening and intervention, and 69.1 % (n = 47) reported motivation to implement the screening and intervention. Finally, 67.6 % (n = 46) felt that community pharmacies are committed to implementing the screening and intervention, but only 10.3 % (n = 7) expressed strong support to do "whatever it takes" to implement the screening and intervention.
These results provide critical insights into implementation strategies for the adoption of brief intervention by community pharmacists. These data are foundational to developing strategies for a powered trial and possible future system/practice-level implementation of universal alcohol screening and intervention for co-use.
开具阿片类药物的患者过量用药的一个重大风险是同时饮酒。社区药房作为预防和解决同时使用问题的资源未得到充分利用。在阿片类药物配药时,促进或阻碍采用通用酒精筛查和干预措施的障碍及促进因素尚不清楚。我们评估了社区药房负责人、药剂师和技术人员对实施基于药房的阿片类药物与酒精同时使用筛查/干预措施的看法。
我们开展了一项多方法研究,包括一次性关键信息访谈并结合一项封闭式调查,以了解药房系统/实践层面通用筛查和干预措施的障碍及促进因素。参与者从犹他州和田纳西州招募,要求其为在职的药房负责人、药剂师或技术人员,会说英语,并认为自己能够就社区药房内的同时使用筛查和干预措施提供反馈。访谈采用实施研究综合框架和实施变革的组织准备情况评估。定性分析包括归纳编码和演绎编码。主题遵循开放式初始编码循环,即从数据中归纳得出编码。
访谈(N = 68)得出的主题包括:a)强调需要克服与同时使用药物的患者相关的污名化问题,并转变思维方式来应对相关挑战和风险;b)需要公司层面的支持、管理层认可;c)需要适当技术来支持工作流程,包括全系统变革以支持社区药房内药物治疗管理服务的整合。然而,药剂师渴望了解自己在筛查患者中的作用,并重申以患者为中心的护理重点以实现这一目标,从而抵消了障碍。在组织准备情况评估中,75%(n = 51)的受访者表示社区药房工作人员希望实施筛查和干预措施,69.1%(n = 47)表示有实施筛查和干预措施的动机。最后,67.6%(n = 46)认为社区药房致力于实施筛查和干预措施,但只有10.3%(n = 7)表示强烈支持“不惜一切代价”实施筛查和干预措施。
这些结果为社区药剂师采用简短干预措施的实施策略提供了关键见解。这些数据是制定有力试验策略以及未来可能在系统/实践层面实施通用酒精同时使用筛查和干预措施的基础。